Since the groundbreaking work of Sørlie T and colleagues (2, 3) at the beginning of the 21st century, BC has been believed to consist of at least four different clinically relevant molecular subtypes, Luminal A, Luminal B, HER2 enriched, and triple-negative, classified according to the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67. The gene discussed is ERBB2; the disease is breast cancer.